Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.

Abstract

High-dose epirubicin is tolerable and is an active single agent in NSCLC. It should be combined with relatively nonmyelosuppressive agents such as cisplatin to try to obtain higher response rates and extend the survival in this disease.